#Big_pharma bets billions on ‘silent’ liver disease
▻https://www.ft.com/content/e6ab5da6-f3c9-11e6-8758-6876151821a6
In recent months, large drugmakers including Allergan, Gilead and Novartis have collectively spent billions of dollars acquiring or licensing medicines designed to treat a liver disease that few people have heard of — non-alcoholic steatohepatitis, or #Nash
“I’m sceptical as to whether this is actually needed for most people,” says Ronny Gal, analyst at Bernstein. “You’re essentially trying to put into chronic treatment forever a broad population that will probably never develop the most serious form of the disease.”